ATLX-1095
/ Alchemab Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 05, 2024
Antibodies from Resilient Individuals: Identifying a Potential Novel Treatment for Huntington's Disease Modification
(HSG 2024)
- "ATLX-1095 identified as novel therapeutic for Huntington's Disease. Currently in development for clinical study starting in late 2025."
Clinical • Huntington's Disease • Movement Disorders • NEFL
1 to 1
Of
1
Go to page
1